As mentioned earlier, NK cell TriKEs combining an NKp46 scFv-binding domain, a CD16 Fc binding domain, and a tumor-associated antigen have been manufactured, leading to augmented ADCC and NK cell cytotoxicity against mouse cancer [72,87,95]. Here, NCR1 is linked to neoplasm.